Breast Cancer Research Council Meeting Minutes May 21, 2004: Funding Meeting Oakland, CA

Members present: Kim Pierce, Elaine Ashby, Debra Oto-Kent, Georjean Stoodt, Carol D'Onofrio, Janet Howard-Espinoza, Michael Figueroa, Vicki Boriak, Christine White, Dorothy Bainton, Diana Chingos, Kathryn Phillips, Jacquline Papkoff, John Morgan, Kathy Walters, Dee Bainton, James Ford

Members not present: Diana Chingos, Georjean Stoodt

Guests: M. Ellen Mahoney, Bobbie Head, Barbara Brenner, Sandra Walsh

Staff: Mhel Kavanaugh-Lynch, Charles L. Gruder, Walter Price, Larry Fitzgerald, Janna Cordeiro, Katie McKenzie, Lyn Dunagan, Jill Stark, Cathyn Fan, David Betts, Joyce Price, Sharon Simms, Brenda Dixon-Coby, Eric Noguchi

I. Call to Order

The meeting was called to order at 8:21am and introductions were exchanged. Deb Oto-Kent briefly reviewed the steps of the programmatic review process.

II. Funding

Approximately \$14.9 million is available for funding this year; that budget number constitutes available funds, returned funds from previous grants, and the assumption that we will end up spending only 95 percent of what we fund this year.

Council members split into their committees to review the applications.

Initial committee recommendations for *primary* applications broke down into the following approximate totals:

Etiology: \$4.8 million
Sociocultural: \$2.7 million
Innovative: \$2.3 million
CRC: \$700,000
Prevention: \$3.5 million
Pathogenesis: \$3.2 million
Tumor: \$3 million

Each committee was asked to voluntarily remove at least one award from the "pay" to the "pay-if" recommendation.

The Council further agreed to reduce all RFA and SPRC application direct cost budgets by 10 percent.

The committees then recommended *complementary* applications for funding. After another round of discussion, the following final funding recommendations were made:

The "Pav" List

The "Pay" List								
			Rec	Approve d Dir.	Total			
Appl No	PI Last Name	Project Title	Dur.	Cost	Indirect	Total Approv	Priority Area	
		Normal Mammary Biology of					Biology of the	
10PB-0127	Walker	Phosphorylated Prolactin	3	\$541,444	\$0	\$541,444	Normal Breast	
		Axon Guidance Proteins in					Biology of the	
10PB-0188	Hinck	Mammary Gland Development	3	\$449,228	\$0	\$449,228	Normal Breast	
		The Role of Gli3 in Mouse						
10FB-0116	Veltmaat	Embryonic Mammary Gland formation	2	\$90,000	\$0	\$90,000	Biology of the Normal Breast	
10110-0110	Veitinaat			\$90,000	φυ	\$90,000		
10FB-0042	Liston	Targeting of DNA Methylation in Mammary Epithelial Cells	2	\$90,000	\$0	\$90,000	Biology of the Normal Breast	
101 10042	LISTOTI			Ψ30,000	ΨΟ	ψ50,000		
10FB-0046	Hodges	Protective Role of Estrogen Receptor Beta in Mammary	2	\$90,000	\$0	\$90,000	Biology of the Normal Breast	
101 15 00 40	riouges			Ψου,σοσ	ΨΟ	Ψου,οοο		
10GB-0095	Kouros-Mehr	In vivo Gene Expression Profiling of Developing Mammary Glan	2	\$60,000	\$0	\$60,000	Biology of the Normal Breast	
100000		Epithelial Polarity, Organization		400,000	4.5		Biology of the	
10IB-0157	Boudreau	and the Angiogenic Switch	2	\$75,000	\$0	\$75,000	Normal Breast	
		Discovering Novel Cell-ECM		, ,	·	• • •	Biology of the	
10IB-0067	Muschler	Interactions in Breast Cells	2	\$100,000	\$60,000	\$160,000	Normal Breast	
		Proteomic Profiling of Adhesive						
10FB-0115	Bush	Structures in Breast Cancer	2	\$90,000	\$0	\$90,000	Pathogenesis	
		The Breast Cancer Suppressor						
10WB-0083	Smith	Maspin: A Proteasome Inhbitor?	1	\$148,877	\$135,847	\$284,724	Pathogenesis	
							Socio-cultural,	
	Ferrier/Koopm	Expanding Rural Access: Distance					Behavioral and	
10AB-2800	an/Kreshka	Delivery of Support Groups	1	\$100,000	\$38,914	\$138,914	Psychological	
		Decision Support in Rural					Socio-cultural,	
40AD 4000	Belkora	Underserved North Coast		# 400 000	Ф4 F 000	Ф44F 000	Behavioral and	
10AB-1600	/O'Donnell	Counties	1	\$100,000	\$15,000	\$115,000	Psychological	
							Socio-cultural,	
10AB-2300	Link/Rakoff/ Maxwell	Peer Mentors Promoting Breast Cancer Clinical Research	2	\$132,218	\$30,126	\$162,344	Behavioral and Psychological	
10AB-2300				\$132,210	φ30,120	φ102,344	rsychological	
10DB-0011	Chen/Palomar es	Grape seed as aromatase inhibitor for breast cancer risk	1	\$99,998	\$71,998	\$171,996	Prevention	
1000-0011	63	101 breast carreer risk	<u> </u>	ψ99,990	Ψ71,990	ψ171,990	i ievenuon	
10DB-0158	Rao/Brooks	Surrogate Markers for Green Tea	1	\$100,000	\$0	\$100,000	Prevention	
1000 0100	rao/Brooks		i i	ψ100,000	ΨΟ	Ψ100,000	Racial-Ethnic	
10FB-0191	Bhatia	Socioeconomics and Ethnicity Affect Tumor Endocrine Status	2	\$90,000	\$0	\$90,000	Differences	
70.000		Control of Aromatase Expression		400,000	4.5			
10GB-0088	Kijima	in Breast Cancer	2	\$60,000	\$0	\$60,000	Etiology	
		Assessment of recurrent genomic		, ,		, ,	Racial-Ethnic	
10IB-0195	Chen	aberrations linked to ethnic	2	\$100,000	\$0	\$100,000	Differences	
		PBDE's in tissues of women with				· · ·		
10IB-0061	Petreas	and without breast cancer	2	\$74,999	\$10,902	\$85,901	Etiology	
		Tea, genes and their interactions						
10PB-0098	Wu	on breast cancer	3	\$990,331	\$689,638	\$1,611,004	Prevention	
		Breast Cancer Prevention with						
10PB-0140	Chen	Phytochemicals in Mushrooms	3	\$445,567	\$356,454	\$766,376	Prevention	
		Birth Characteristics and Breast						
10PB-0165	Reynolds	Cancer in Young Women	3	\$783,569	\$136,464	\$906,386	Etiology	
		Breast Cancer Chemoprevention						
10WB-0179	Leitman	with Dietary Herbal Estrogens	2	\$200,000	\$0	\$200,000	Prevention	

10EB-0168	Faris/Birdwell	Differential Optical Mammography	3	\$501,147	\$357,944	\$823,297	Earlier Detection
10EB-0208	Hylton/Tromb erg	Breast Cancer Functional Imaging with Optics and MRI	3	\$500,000	\$0	\$500,000	Earlier Detection
10GB-0001	Edwards	The Functional Implications of Taxane-induced Neuropathy	2	\$54,713	\$0	\$54,713	Socio-cultural, Behavioral and Psychological
10WB-0010	Lustgarten	Her-2/neu-crosreactive analogs as targets for breast cancer	2	\$200,000	\$172,600	\$372,600	Innovative Treatment
10WB-0194	Pellecchia	Novel Agents for Breast Cancer Therapy	2	\$149,615	\$136,149	\$285,764	Innovative Treatment
10YB-0125	Benz/Gibson	Oxidative Stress and Estrogen Receptor Structural Changes	3	\$661,753	\$589,147	\$1,125,810	Pathogenesis
10FB-0166	East	Hox transcriptional regulation of breast tumor angiogenesis	2	\$90,000	\$0	\$90,000	Pathogenesis
10GB-0104	So	Inactivation of Estrogen Receptor by its Ligand-binding Doma	2	\$60,000	\$0	\$60,000	Pathogenesis
10IB-0077	Kulp	Identifying Metastatic Breast Cells from Peripheral Blood	1	\$100,000	\$110,159	\$210,159	Pathogenesis
10IB-0073	Carlson	Characterizing Breast Cancer Cells in Blood and Bone Marrow	1	\$97,680	\$58,428	\$156,108	Pathogenesis
10FB-0049	Johnston	Empowering Acupuncturists to Cooperate with Oncologists	2	\$89,728	\$0	\$89,728	Health Policy and Health Svcs
10IB-0079	Stanton	Living Well With Advanced Breast Cancer: A Predictive Model	2	\$99,982	\$0	\$99,982	Socio-cultural, Behavioral and Psychological
10PB-0064	Bloom	Young Breast Cancer Survivors: Ten Years Later	3	\$944,961	\$0	\$944,961	Socio-cultural, Behavioral and Psychological
10PB-0012	Klonoff-Cohen	Hormone, Psychologic & Immunologic Factors & BC Survivorship	3	\$1,196,1 66	\$0	\$1,196,166	Socio-cultural, Behavioral and Psychological
10IB-0048	Wellisch	Psychobiological concomitants of bereaved women @ br ca risk	2	\$118,755	\$0	\$118,755	Socio-cultural, Behavioral and Psychological
10EB-0086	Cravatt/Jeffrey	Profiling Enzyme Activities in Human Breast Cancer	2	\$500,000	\$391,175	\$891,175	Pathogenesis
10YB-0202	Yates/Felding- Habermann	Stem Cells in Breast Cancer Metastasis	2	\$670,200	\$300,000	\$906,990	Pathogenesis
10FB-0152	Sieber	A proteomic strategy for inhibiting breast cancer enzymes	2	\$90,000	\$0	\$90,000	Pathogenesis
10FB-0122	Fong	FKBP Proteins as Molecular Targets in Breast Cancer Therapy	2	\$89,988	\$0	\$89,988	Innovative Treatment
10FB-0090	Bailly-Maitre	Role of Bl-1 protein in Pathogenesis of Breast Cancers	2	\$90,000	\$0	\$90,000	Pathogenesis

total funding: \$14,634,513

tax checkoff

faith fancher award

The "Pay-if" List

	PI Last		Rec.	Approved	Total		
Appl No	Name	Project Title	Dur.	Dir. Cost	Indirect	Total Approv	Priority Area
		Roles of Src and p130Cas in					
10GB-0094	Kangas	Breast Cancer	2	\$60,000	\$0	\$60,000	Pathogenesis

10WB- 0175	Borgstrom/ Deisseroth	Vector Mediated Vascular Targeting Therapy of Breast Cancer	2	\$200,000	\$172,600	\$372,600	Innovative Treatment Modalities
10WB- 0124	Kono	A New Contrast Agent for MRI Detection of Breast Cancer	2	\$199,955	\$0	\$199,955	Earlier Detection
10DB-0027	Jong/Maniar /Parker	A novel phospho-Akt inhibitor for breast cancer therapy	1	\$100,000	\$101,385	\$201,385	Innovative Treatment Modalities
10EB-0018	Boone/ Nelson /Lindfors	Precision-guided Robotic Breast Biopsy	3	\$500,000	\$0	\$500,000	Earlier Detection
10EB-0037	Vera/ Wallace	Comparison of Two Sentinel Node Mapping Agents	2	\$337,893	\$0	\$337,893	Earlier Detection
10IB-0075	Henderson	IGF Receptors and Breast Cancer Risk: The Multiethnic Cohort	2	\$100,000	\$62,500	\$162,500	Prevention
10IB-0041	Klifa	Study of Breast Composition Using Optical and MR Imaging	2	\$100,000	\$0	\$100,000	Biology of the Normal Breast
10KB-0044	Herman	Breast Cancer Prevention Trial: Lifestyle and Cancer Risk	3	\$300,000	\$0	\$300,000	Prevention
10WB- 0193	Kolluri	A Clinically Approved Painkiller for Breast Cancer Treatment	2	\$200,000	\$182,000	\$382,000	Prevention
10WB- 0215	Dawson	Breast Cancer Prevention by 3-C-AHPC in Bitransgenic Mice	2	\$102,199	\$93,001	\$195,200	Prevention
10WB- 0147	Smitt	Molecular Phenotypes of South Asian Breast Cancer	2	\$249,721	\$149,832	\$399,553	Racial-Ethnic Differences
10AB-2700	Smitt/Giese- Davis	Is Peer Navigator Viable in an Ethnically Diverse Hospital	2	\$104,358	\$49,777	\$154,135	Health Policy and Health Services
10PB-0171	Luce	Ethnically Tailored Genetic Education for Hereditary Breast	3	\$562,442	\$0	\$562,442	Racial-Ethnic Differences
10FB-0161	Krig	ZNF217 Interference with Cell Death Pathways	2	\$90,000	\$0	\$90,000	Pathogenesis
10FB-0087	de Mollerat	A Novel Exchange Complex in Estrogen Receptor Function	2	\$90,000	\$0	\$90,000	Pathogenesis Biology of the
10IB-0143	Andersen	Hormonal Regulation on Mammary Gland Stem Cells	2	\$100,000	\$0	\$100,000	Normal Breast
10PB-0181	Plevritis	Genomic Instability in Women at High Risk of Breast Cancer	3	\$622,624	\$271,160	\$893,784	Biology of the Normal Breast

Motion: A motion was made by Vicki Boriak and seconded by Michael Figueroa to recommend the above "pay" list of applications for funding. The motion passed unanimously.

A request was made that council members be notified should the 10 percent reduction in funding (RFAs and SPRCs) make a project untenable. Staff will do so.

Council members selected the tax check-off and Faith Fancher Research award recipients from the funding list.

Council members ranked the pay-if applications in their committees. Applications that were initially selected for funding consideration but were removed during discussions will receive first priority. Staff will rank the remaining pay-ifs.

Tax Check-off Awards

Individual taxpayer contributions made through Form 540—the California state income tax return—directly support community research projects. Each year, the Council apportions the roughly \$600,000 of taxpayer contributions to research projects that most directly affect the community.

Faith Fancher Research Award

Faith Fancher was a long-time television personality with KTVU in Oakland who waged a very public battle against breast cancer. She also was the founding member of the CBCRP Executive Team, which formed in 2001 to help raise the visibility and fundraising profile of our program. Faith passed away in October 2003 after a six-year struggle with breast cancer.

In Faith's honor, and to commemorate all that Faith Fancher did for breast cancer education and research, we have created the annual Faith Fancher Research award, which will be given each July to a researcher, institution, or community-based organization whose work reflects those values that Faith held most closely. This award will fund a breast cancer research project in our portfolio that will extend Faith's work, such as a Community Research Collaboration award or a project in our Racial and Ethnic Differences portfolio, one of our high priority funding issues.

III. Old Business

A. Council Chair and Vice-Chair Nominations

Vicki Boriak nominated Deb Oto-Kent for Chair; Elaine Ashby seconded. There were no other nominations for Chair.

Deb Oto-Kent nominated Jackie Papkoff for Vice-Chair; Michael Figueroa seconded. There were no other nominations for Vice-Chair.

There were no self-nominations for either Chair or Vice-Chair.

B. Cycle 11 Call for Applications

Council members were asked to review the Call for Applications and notify staff of any problems or concerns *before* the June meeting.

C. Announcements

Kathryn Phillips is resigning from the Council as of today.

All other Old Business was postponed until the June meeting in San Diego.

The meeting was adjourned at 4:20pm.